Funding for this research was provided by:
PTC Therapeutics
Article History
Received: 12 May 2021
Accepted: 23 November 2021
First Online: 11 December 2021
Declarations
:
: The study was submitted for review to the University of York’s Health Sciences Research Governance Committee and received ethics approval on 20 March 2020, and was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: KB is an employee of PTC Therapeutics, the manufacturer of PTC-AADC, a candidate gene therapy for the treatment of AADC deficiency.